EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL

EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL F. Morschhauser | N. Ghosh | I. Lossos | M.L. Palomba | A. Mehta | O. Casasnovas | D. Stevens | S. Chitra | A. Knapp | T. Nielsen | M. Oestergaard | M. Wenger | G. Salles Institute of Hematology-Transfusion, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, United States; Division of Hematology, Department of Medicine, University of Miami, Miami, FL, United States; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Division of Hematology and Oncology, University of Alabama School of Medicine, Birmingham, Alabama, United States; Service d'Hématologie clinique, CHU Dijon Bourgogne Hôpital François Mitterrand, Dijon, France; Norton Cancer Institute, Norton Healthcare, Louisville, KY, United States; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Haematology Department, Université Claude Bernard de Lyon, Lyon University Hospital, Villeurbanne, France